Thera-SAbDab

LINTUZUMAB

>   Structural Summary
TherapeuticLintuzumab
TargetCD33
Heavy ChainQVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYNMHWVRQAPGQGLEWIGYIYPYNGGTGYNQKFKSKATITADESTNTAYMELSSLRSEDTAVYYCARGRPAMDYWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCRASESVDNYGISFMNWFQQKPGKAPKLLIYAASNQGSGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQSKEVPWTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb Radiolabelled
IsotypeG1
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Discontinued
Recorded Developmental Technologyna
INN Year Proposed1996
INN Year Recommended1997
Companies InvolvedPDL BioPharma, Seattle Genetics
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedAcute myeloid leukaemia, Myelodysplastic syndromes
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]